BRPI0108395B8 - derivados de pirrolopirimidinona, processos de preparação e uso - Google Patents

derivados de pirrolopirimidinona, processos de preparação e uso

Info

Publication number
BRPI0108395B8
BRPI0108395B8 BRPI0108395A BR0108395A BRPI0108395B8 BR PI0108395 B8 BRPI0108395 B8 BR PI0108395B8 BR PI0108395 A BRPI0108395 A BR PI0108395A BR 0108395 A BR0108395 A BR 0108395A BR PI0108395 B8 BRPI0108395 B8 BR PI0108395B8
Authority
BR
Brazil
Prior art keywords
preparation
use processes
pyrrolopyrimidinone derivatives
pyrrolopyrimidinone
derivatives
Prior art date
Application number
BRPI0108395A
Other languages
English (en)
Other versions
BRPI0108395B1 (pt
BR0108395A (pt
Inventor
Kim Dae-Kee
Hyun Ryu Do
Im Guang-Jin
Cha Hoon
Kim Jae-Sum
Ho Ryu Je
Choi Jin-Young
Young Lee Ju
Kyu Lee Nam
Kim Nam-Ho
Ho Lee Suk
Kon Kim Tae
Choi Won-Son
Original Assignee
In2Gen Co Ltd
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In2Gen Co Ltd, Sk Chemicals Co Ltd filed Critical In2Gen Co Ltd
Publication of BR0108395A publication Critical patent/BR0108395A/pt
Publication of BRPI0108395B1 publication Critical patent/BRPI0108395B1/pt
Publication of BRPI0108395B8 publication Critical patent/BRPI0108395B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"derivados de pirrolopirimidinona, processos de preparação e uso". a invenção se refere a uma série de derivados de pirrolopirimidinona da fórmula (1), processos para a preparação dos mesmos, intermediários na preparação dos mesmos, uso dos mesmos como agentes terapêuticos e composições farmacêuticas contendo os mesmos.
BRPI0108395A 2000-02-17 2001-02-15 derivados de pirrolopirimidinona, processos de preparação e uso BRPI0108395B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000007625A KR100358083B1 (ko) 2000-02-17 2000-02-17 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
PCT/KR2001/000227 WO2001060825A1 (en) 2000-02-17 2001-02-15 Pyrrolopyrimidinone derivatives, process of preparation and use

Publications (3)

Publication Number Publication Date
BR0108395A BR0108395A (pt) 2003-03-11
BRPI0108395B1 BRPI0108395B1 (pt) 2017-06-06
BRPI0108395B8 true BRPI0108395B8 (pt) 2021-05-25

Family

ID=19647449

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108395A BRPI0108395B8 (pt) 2000-02-17 2001-02-15 derivados de pirrolopirimidinona, processos de preparação e uso

Country Status (23)

Country Link
US (1) US6962911B2 (pt)
EP (1) EP1257553B1 (pt)
JP (1) JP4845076B2 (pt)
KR (1) KR100358083B1 (pt)
CN (1) CN1312153C (pt)
AT (1) ATE267829T1 (pt)
AU (2) AU2001236140B9 (pt)
BR (1) BRPI0108395B8 (pt)
CA (1) CA2400268C (pt)
DE (1) DE60103508T2 (pt)
DK (1) DK1257553T3 (pt)
ES (1) ES2222344T3 (pt)
HU (1) HU230344B1 (pt)
IL (2) IL151234A0 (pt)
MX (1) MXPA02007942A (pt)
NO (1) NO323553B1 (pt)
NZ (1) NZ520842A (pt)
PL (1) PL210796B1 (pt)
PT (1) PT1257553E (pt)
RU (1) RU2263676C2 (pt)
TR (1) TR200402101T4 (pt)
WO (1) WO2001060825A1 (pt)
ZA (1) ZA200206587B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
EP1362858A1 (en) * 2002-05-15 2003-11-19 SK Chemicals Co., Ltd. Pyrrolopyrimidinone derivates, process of preparation and use
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
CA2666696C (en) * 2006-07-03 2013-01-15 Sk Chemicals Co., Ltd. Salts of pyrrolopyrimidinone derivatives and process for preparing the same
KR20080003599A (ko) * 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
NZ599290A (en) 2009-10-16 2014-10-31 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EA201270566A1 (ru) 2009-10-16 2012-11-30 Риб-Экс Фармасьютикалз, Инк. Противомикробные соединения и способы их получения и применения
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
TWI490220B (zh) * 2011-04-04 2015-07-01 Sk Chemicals Co Ltd 包含ｐｄｅ５抑制劑之用於減少皮膚皺紋之組成物
MY173518A (en) * 2011-04-15 2020-01-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
CN103826638B (zh) 2011-09-09 2015-11-25 Sk化学公司 含有pde5 抑制剂的减少皮肤皱纹的组合物
US9750743B2 (en) 2012-12-04 2017-09-05 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
HK1249758A1 (zh) 2015-03-11 2018-11-09 Melinta Therapeutics, Inc. 抗微生物化合物及其制备和使用方法
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
KR102670626B1 (ko) * 2017-05-22 2024-05-29 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
JP7596257B2 (ja) * 2018-08-06 2024-12-09 ニコックス エス．エー． 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬
WO2020109354A1 (en) 2018-11-28 2020-06-04 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102900330B1 (ko) * 2020-07-16 2025-12-15 제이투에이치바이오텍 (주) 이중 억제제 화합물 및 이들의 의약 용도
CN111825593B (zh) * 2020-08-19 2023-04-07 上海成澄科技有限公司 3-氨基吡咯-2-甲酰胺类化合物的合成方法
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
CA3228160A1 (en) 2021-09-29 2023-04-06 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
JP2025506878A (ja) 2022-03-02 2025-03-13 トパデュール ファルマ アーゲー 局所組成物及びその使用
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5761734B2 (pt) * 1973-09-27 1982-12-25 Takeda Chemical Industries Ltd
JPS5761734A (en) * 1980-10-02 1982-04-14 Teijin Ltd Spun like fabric
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
RU2097394C1 (ru) * 1996-02-06 1997-11-27 Открытое акционерное общество "Акрон" Пресс-масса для изготовления древесно-стружечных плит
EP0977756A1 (en) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
HRP20000712A2 (en) * 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도

Also Published As

Publication number Publication date
ATE267829T1 (de) 2004-06-15
EP1257553A1 (en) 2002-11-20
DK1257553T3 (da) 2004-10-04
NO20023823D0 (no) 2002-08-13
PL358188A1 (en) 2004-08-09
IL151234A0 (en) 2003-04-10
PL210796B1 (pl) 2012-03-30
RU2263676C2 (ru) 2005-11-10
DE60103508D1 (de) 2004-07-01
AU2001236140B9 (en) 2006-08-31
RU2002124872A (ru) 2004-01-10
AU3614001A (en) 2001-08-27
HU230344B1 (hu) 2016-02-29
US20030171361A1 (en) 2003-09-11
JP2003523344A (ja) 2003-08-05
KR20010083637A (ko) 2001-09-01
WO2001060825A1 (en) 2001-08-23
AU2001236140B2 (en) 2006-01-12
HUP0300527A3 (en) 2012-10-29
DE60103508T2 (de) 2005-06-30
BRPI0108395B1 (pt) 2017-06-06
KR100358083B1 (ko) 2002-10-25
BR0108395A (pt) 2003-03-11
EP1257553B1 (en) 2004-05-26
ES2222344T3 (es) 2005-02-01
NO323553B1 (no) 2007-06-11
CA2400268A1 (en) 2001-08-23
CN1312153C (zh) 2007-04-25
HUP0300527A2 (hu) 2003-07-28
NZ520842A (en) 2004-04-30
MXPA02007942A (es) 2004-09-10
IL151234A (en) 2010-05-17
US6962911B2 (en) 2005-11-08
TR200402101T4 (tr) 2004-10-21
ZA200206587B (en) 2003-10-09
PT1257553E (pt) 2004-10-29
NO20023823L (no) 2002-10-09
CA2400268C (en) 2009-08-18
JP4845076B2 (ja) 2011-12-28
CN1422271A (zh) 2003-06-04

Similar Documents

Publication Publication Date Title
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
SE9904505D0 (sv) Novel compounds
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
MXPA03005464A (es) Agentes antivirales.
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
SE0001899D0 (sv) New compounds
IS6520A (is) Ný efnasambönd
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
BR0211473A (pt) Novos compostos
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
IS6658A (is) Ný efnasambönd
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
SE0100569D0 (sv) New compounds
NO20020282L (no) Nytt difenyl-piperidinderivat
BR0111678A (pt) Composições medicinais contendo derivados de propenona
SE0102055D0 (sv) New Compounds
BG101605A (bg) Ентерокинетични бензамиди
ATE253359T1 (de) Antithrombotische mittel
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PA8509601A1 (es) "PIRAZOLO [4,3,e] DIAZEPINAS SUSTITUIDAS NOVEDOSAS, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN, SU USO COMO PRODUCTOS MEDICINALES Y PROCESOS PARA PREPARARLAS

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. C07D 487/04, A61K 31/519, C07D 207/34, A61P 9/00

Ipc: C07D 487/04 (2006.01), A61K 31/519 (2006.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/02/2021